Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521122 | 0.88 | CNR1 (0.49) | CNR1IDO1CNR2 | |
| SCHEMBL3518278 | 0.86 | CNR1 (0.66) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3520860 | 0.86 | CNR1 (0.66) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3520722 | 0.83 | CNR1 (0.62) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3518685 | 0.80 | CNR1 (0.59) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5565960 | 0.78 | CNR1 (0.80) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3522225 | 0.78 | CNR1 (0.60) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3519768 | 0.78 | CNR1 (0.56) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5567975 | 0.77 | CNR1 (0.98) | CNR1 | |
| SCHEMBL29164634 | 0.75 | HTT (0.60) | IDO1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919471-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | MERCK SHARP & DOHME (NL) | 2014-01-08 | — | — | EP | disclosed |
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | disclosed |
| US-20070082931-A1 | Indole derivatives | AKZO NOBLE N.V. (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082931-A1 | Indole derivatives | IDO1, TPH1, IDO2 | CNR1 36/4885IDO1 1/4885CNR2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.